References:
1. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in Children
and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J
Med . Feb 1 2018;378(5):439-448. doi:10.1056/NEJMoa1709866
2. Frangoul H, Altshuler D, Cappellini MD, et al. CRISPR-Cas9 Gene
Editing for Sickle Cell Disease and beta-Thalassemia. N Engl J
Med . Jan 21 2021;384(3):252-260. doi:10.1056/NEJMoa2031054
3. Locatelli F, Thompson AA, Kwiatkowski JL, et al. Betibeglogene
Autotemcel Gene Therapy for Non-beta(0)/beta(0) Genotype
beta-Thalassemia. N Engl J Med . Feb 3 2022;386(5):415-427.
doi:10.1056/NEJMoa2113206
4. Pulsipher MA, Langholz B, Wall DA, et al. The addition of sirolimus
to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a
phase 3 Children’s Oncology Group/Pediatric Blood and Marrow Transplant
Consortium trial. Blood . Mar 27 2014;123(13):2017-25.
doi:10.1182/blood-2013-10-534297
5. Pulsipher MA, Langholz B, Wall DA, et al. Risk factors and timing of
relapse after allogeneic transplantation in pediatric ALL: for whom and
when should interventions be tested? Bone Marrow Transplant . Sep
2015;50(9):1173-9. doi:10.1038/bmt.2015.103
6. Bader P, Salzmann-Manrique E, Balduzzi A, et al. More precisely
defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures,
serial positivity, and risk modeling. Blood Adv . Nov 12
2019;3(21):3393-3405. doi:10.1182/bloodadvances.2019000449
7. Pulsipher MA, Carlson C, Langholz B, et al. IgH-V(D)J NGS-MRD
measurement pre- and early post-allotransplant defines very low- and
very high-risk ALL patients. Blood . May 28 2015;125(22):3501-8.
doi:10.1182/blood-2014-12-615757
8. Peters C, Dalle JH, Locatelli F, et al. Total Body Irradiation or
Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized,
Noninferiority Phase III Study. J Clin Oncol . Feb 1
2021;39(4):295-307. doi:10.1200/JCO.20.02529
9. Bunin N, Aplenc R, Kamani N, Shaw K, Cnaan A, Simms S. Randomized
trial of busulfan vs total body irradiation containing conditioning
regimens for children with acute lymphoblastic leukemia: a Pediatric
Blood and Marrow Transplant Consortium study. Bone Marrow
Transplant . Sep 2003;32(6):543-8. doi:10.1038/sj.bmt.1704198
10. Gupta V, Braun TM, Chowdhury M, Tewari M, Choi SW. A Systematic
Review of Machine Learning Techniques in Hematopoietic Stem Cell
Transplantation (HSCT). Sensors (Basel) . Oct 27
2020;20(21)doi:10.3390/s20216100
11. Locatelli F, Crotta A, Ruggeri A, et al. Analysis of risk factors
influencing outcomes after cord blood transplantation in children with
juvenile myelomonocytic leukemia: a EUROCORD, EBMT, EWOG-MDS, CIBMTR
study. Blood . Sep 19 2013;122(12):2135-41.
doi:10.1182/blood-2013-03-491589
12. Yabe M, Ohtsuka Y, Watanabe K, et al. Transplantation for juvenile
myelomonocytic leukemia: a retrospective study of 30 children treated
with a regimen of busulfan, fludarabine, and melphalan. Int J
Hematol . Feb 2015;101(2):184-90. doi:10.1007/s12185-014-1715-7
13. Dvorak CC, Satwani P, Stieglitz E, et al. Disease burden and
conditioning regimens in ASCT1221, a randomized phase II trial in
children with juvenile myelomonocytic leukemia: A Children’s Oncology
Group study. Pediatr Blood Cancer . Jul 2018;65(7):e27034.
doi:10.1002/pbc.27034
14. Kurtzberg J, Prasad VK, Carter SL, et al. Results of the Cord Blood
Transplantation Study (COBLT): clinical outcomes of unrelated donor
umbilical cord blood transplantation in pediatric patients with
hematologic malignancies. Blood . Nov 15 2008;112(10):4318-27.
doi:10.1182/blood-2007-06-098020
15. Cornetta K, Laughlin M, Carter S, et al. Umbilical cord blood
transplantation in adults: results of the prospective Cord Blood
Transplantation (COBLT). Biol Blood Marrow Transplant . Feb
2005;11(2):149-60. doi:10.1016/j.bbmt.2004.11.020
16. Brunstein CG, Barker JN, Weisdorf DJ, et al. Umbilical cord blood
transplantation after nonmyeloablative conditioning: impact on
transplantation outcomes in 110 adults with hematologic disease.Blood . Oct 15 2007;110(8):3064-70.
doi:10.1182/blood-2007-04-067215
17. Wagner JE, Jr., Eapen M, Carter S, et al. One-unit versus two-unit
cord-blood transplantation for hematologic cancers. N Engl J Med .
Oct 30 2014;371(18):1685-94. doi:10.1056/NEJMoa1405584
18. Kreissman SG, Seeger RC, Matthay KK, et al. Purged versus non-purged
peripheral blood stem-cell transplantation for high-risk neuroblastoma
(COG A3973): a randomised phase 3 trial. Lancet Oncol . Sep
2013;14(10):999-1008. doi:10.1016/S1470-2045(13)70309-7
19. Seif AE, Naranjo A, Baker DL, et al. A pilot study of tandem
high-dose chemotherapy with stem cell rescue as consolidation for
high-risk neuroblastoma: Children’s Oncology Group study ANBL00P1.Bone Marrow Transplant . Jul 2013;48(7):947-52.
doi:10.1038/bmt.2012.276
20. Grupp SA, Stern JW, Bunin N, et al. Tandem high-dose therapy in
rapid sequence for children with high-risk neuroblastoma. J Clin
Oncol . Jul 2000;18(13):2567-75. doi:10.1200/JCO.2000.18.13.2567
21. Park JR, Kreissman SG, London WB, et al. Effect of Tandem Autologous
Stem Cell Transplant vs Single Transplant on Event-Free Survival in
Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial.JAMA . Aug 27 2019;322(8):746-755. doi:10.1001/jama.2019.11642
22. Ladenstein R, Potschger U, Pearson ADJ, et al. Busulfan and
melphalan versus carboplatin, etoposide, and melphalan as high-dose
chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an
international, randomised, multi-arm, open-label, phase 3 trial.Lancet Oncol . Apr 2017;18(4):500-514.
doi:10.1016/S1470-2045(17)30070-0
23. Granger MM, Naranjo A, Bagatell R, et al. Myeloablative
Busulfan/Melphalan Consolidation following Induction Chemotherapy for
Patients with Newly Diagnosed High-Risk Neuroblastoma: Children’s
Oncology Group Trial ANBL12P1. Transplant Cell Ther . Jun
2021;27(6):490 e1-490 e8. doi:10.1016/j.jtct.2021.03.006
24. Reddy AT, Strother DR, Judkins AR, et al. Efficacy of High-Dose
Chemotherapy and Three-Dimensional Conformal Radiation for Atypical
Teratoid/Rhabdoid Tumor: A Report From the Children’s Oncology Group
Trial ACNS0333. J Clin Oncol . Apr 10 2020;38(11):1175-1185.
doi:10.1200/JCO.19.01776
25. Rare Tumors in Kids May Respond to Tazemetostat. Cancer
Discov . Jan 2018;8(1):OF5. doi:10.1158/2159-8290.CD-NB2017-152
26. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor
natural killer cell alloreactivity in mismatched hematopoietic
transplants. Science . Mar 15 2002;295(5562):2097-100.
doi:10.1126/science.1068440
27. Hsu KC, Keever-Taylor CA, Wilton A, et al. Improved outcome in
HLA-identical sibling hematopoietic stem-cell transplantation for acute
myelogenous leukemia predicted by KIR and HLA genotypes. Blood .
Jun 15 2005;105(12):4878-84. doi:10.1182/blood-2004-12-4825
28. Davies SM, Ruggieri L, DeFor T, et al. Evaluation of KIR ligand
incompatibility in mismatched unrelated donor hematopoietic transplants.
Killer immunoglobulin-like receptor. Blood . Nov 15
2002;100(10):3825-7. doi:10.1182/blood-2002-04-1197
29. Horan JT, Alonzo TA, Lyman GH, et al. Impact of disease risk on
efficacy of matched related bone marrow transplantation for pediatric
acute myeloid leukemia: the Children’s Oncology Group. J Clin
Oncol . Dec 10 2008;26(35):5797-801. doi:10.1200/JCO.2007.13.5244
30. Masetti R, Muratore E, Gori D, Prete A, Locatelli F. Allogeneic
hematopoietic stem cell transplantation for pediatric acute myeloid
leukemia in first complete remission: a meta-analysis. Ann
Hematol . Nov 2022;101(11):2497-2506. doi:10.1007/s00277-022-04965-x
31. Pollard JA, Alonzo TA, Gerbing R, et al. Sorafenib in Combination
With Standard Chemotherapy for Children With High Allelic Ratio
FLT3/ITD+ Acute Myeloid Leukemia: A Report From the Children’s Oncology
Group Protocol AAML1031. J Clin Oncol . Jun 20
2022;40(18):2023-2035. doi:10.1200/JCO.21.01612
32. Brown PA, Ji L, Xu X, et al. Effect of Postreinduction Therapy
Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival
in Children, Adolescents, and Young Adults With First Relapse of B-Cell
Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA .
Mar 2 2021;325(9):833-842. doi:10.1001/jama.2021.0669
33. Alexander S, Fisher BT, Gaur AH, et al. Effect of Levofloxacin
Prophylaxis on Bacteremia in Children With Acute Leukemia or Undergoing
Hematopoietic Stem Cell Transplantation: A Randomized Clinical Trial.JAMA . Sep 11 2018;320(10):995-1004. doi:10.1001/jama.2018.12512
34. Dvorak CC, Fisher BT, Esbenshade AJ, et al. A Randomized Trial of
Caspofungin vs Triazoles Prophylaxis for Invasive Fungal Disease in
Pediatric Allogeneic Hematopoietic Cell Transplant. J Pediatric
Infect Dis Soc . Apr 30 2021;10(4):417-425. doi:10.1093/jpids/piaa119
35. Otto WR, Dvorak CC, Boge CLK, et al. Prospective Evaluation of the
Fungitell(R) (1–>3) Beta-D-Glucan Assay as a Diagnostic
Tool for Invasive Fungal Disease in Pediatric Allogeneic Hematopoietic
Cell Transplantation: A Report from the Children’s Oncology Group.Pediatr Transplant . Feb 2023;27(1):e14399. doi:10.1111/petr.14399
36. Andolina JR, Wang YC, Ji L, et al. Adolescent and young adult (AYA)
versus pediatric patients with acute leukemia have a significantly
increased risk of acute GVHD following unrelated donor (URD) stem cell
transplantation (SCT): the Children’s Oncology Group experience.Bone Marrow Transplant . Mar 2022;57(3):445-452.
doi:10.1038/s41409-021-01558-6
37. Qayed M, Wang T, Hemmer MT, et al. Influence of Age on Acute and
Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow
Transplantation for Acute Leukemia: Implications for Prophylaxis.Biol Blood Marrow Transplant . Mar 2018;24(3):521-528.
doi:10.1016/j.bbmt.2017.11.004
38. Nguyen CL, Docampo MD, van den Brink MR, Markey KA. The role of the
intestinal microbiota in allogeneic HCT: clinical associations and
preclinical mechanisms. Curr Opin Genet Dev . Feb 2021;66:25-35.
doi:10.1016/j.gde.2020.11.007
39. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells
for sustained remissions in leukemia. N Engl J Med . Oct 16
2014;371(16):1507-17. doi:10.1056/NEJMoa1407222
40. Schultz LM, Baggott C, Prabhu S, et al. Disease Burden Affects
Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia
After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric
Antigen Receptor Consortium Report. J Clin Oncol . Mar 20
2022;40(9):945-955. doi:10.1200/JCO.20.03585
41. Symons HJ, Zahurak M, Cao Y, et al. Myeloablative haploidentical BMT
with posttransplant cyclophosphamide for hematologic malignancies in
children and adults. Blood Adv . Aug 25 2020;4(16):3913-3925.
doi:10.1182/bloodadvances.2020001648
42. Merli P, Pagliara D, Mina T, et al. alphabetaT- and B-cell-depleted
HLA-haploidentical hematopoietic stem cell transplantation in children
with myelodysplastic syndromes. Haematologica . Dec 1
2022;107(12):2966-2971. doi:10.3324/haematol.2022.280698
43. Gragert L, Eapen M, Williams E, et al. HLA match likelihoods for
hematopoietic stem-cell grafts in the U.S. registry. N Engl J
Med . Jul 24 2014;371(4):339-48. doi:10.1056/NEJMsa1311707
44. Teira P, Battiwalla M, Ramanathan M, et al. Early cytomegalovirus
reactivation remains associated with increased transplant-related
mortality in the current era: a CIBMTR analysis. Blood . May 19
2016;127(20):2427-38. doi:10.1182/blood-2015-11-679639
45. Marty FM, Ljungman P, Chemaly RF, et al. Letermovir prophylaxis for
cytomegalovirus in hematopoietic-cell transplantation. N Engl J
Med . Dec 21 2017;377(25):2433-2444. doi:10.1056/NEJMoa1706640
46. Whangbo JS, Kim HT, Mirkovic N, et al. Dose-escalated interleukin-2
therapy for refractory chronic graft-versus-host disease in adults and
children. Blood Adv . Sep 10 2019;3(17):2550-2561.
doi:10.1182/bloodadvances.2019000631
47. Koreth J, Kim HT, Jones KT, et al. Efficacy, durability, and
response predictors of low-dose interleukin-2 therapy for chronic
graft-versus-host disease. Blood . Jul 7 2016;128(1):130-7.
doi:10.1182/blood-2016-02-702852
48. Koreth J, Matsuoka K, Kim HT, et al. Interleukin-2 and regulatory T
cells in graft-versus-host disease. N Engl J Med . Dec 1
2011;365(22):2055-66. doi:10.1056/NEJMoa1108188
49. Aljebab F, Choonara I, Conroy S. Systematic Review of the Toxicity
of Long-Course Oral Corticosteroids in Children. PLoS One .
2017;12(1):e0170259. doi:10.1371/journal.pone.0170259
50. Etra A, Capellini A, Alousi A, et al. Effective treatment of
low-risk acute GVHD with itacitinib monotherapy. Blood . Feb 2
2023;141(5):481-489. doi:10.1182/blood.2022017442
51. Motta CM, Keller MD, Bollard CM. Applications of virus-specific T
cell therapies post-BMT. Semin Hematol . Jan 2023;60(1):10-19.
doi:10.1053/j.seminhematol.2022.12.002
52. Hont AB, Cruz CR, Ulrey R, et al. Immunotherapy of Relapsed and
Refractory Solid Tumors With Ex Vivo Expanded Multi-Tumor Associated
Antigen Specific Cytotoxic T Lymphocytes: A Phase I Study. J Clin
Oncol . Sep 10 2019;37(26):2349-2359. doi:10.1200/JCO.19.00177
53. Elmas E, Saljoughian N, de Souza Fernandes Pereira M, et al. CRISPR
Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy.Front Oncol . 2022;12:834002. doi:10.3389/fonc.2022.834002
54. Kinoshita H, Cooke KR, Grant M, et al. Outcome of donor-derived
TAA-T cell therapy in patients with high-risk or relapsed acute leukemia
post allogeneic BMT. Blood Adv . Apr 26 2022;6(8):2520-2534.
doi:10.1182/bloodadvances.2021006831
55. Naik S, Vasileiou S, Tzannou I, et al. Donor-derived multiple
leukemia antigen-specific T-cell therapy to prevent relapse after
transplant in patients with ALL. Blood . Apr 28
2022;139(17):2706-2711. doi:10.1182/blood.2021014648
56. Shalabi H, Qin H, Su A, et al. CD19/22 CAR T cells in children and
young adults with B-ALL: phase 1 results and development of a novel
bicistronic CAR. Blood . Aug 4 2022;140(5):451-463.
doi:10.1182/blood.2022015795
57. Yanik GA, Mineishi S, Levine JE, et al. Soluble tumor necrosis
factor receptor: enbrel (etanercept) for subacute pulmonary dysfunction
following allogeneic stem cell transplantation. Biol Blood Marrow
Transplant . Jul 2012;18(7):1044-54. doi:10.1016/j.bbmt.2011.11.031
58. Schofield HT, Fabrizio VA, Braniecki S, et al. Monitoring
Neurocognitive Functioning After Pediatric Cellular Therapy or
Hematopoietic Cell Transplant: Guidelines From the COG Neurocognition in
Cellular Therapies Task Force. Transplant Cell Ther . Oct
2022;28(10):625-636. doi:10.1016/j.jtct.2022.06.027
59. Zerr DM, Milstone AM, Dvorak CC, et al. Chlorhexidine gluconate
bathing in children with cancer or those undergoing hematopoietic stem
cell transplantation: A double-blinded randomized controlled trial from
the Children’s Oncology Group. Cancer . Jan 1 2021;127(1):56-66.
doi:10.1002/cncr.33271
Figure 1 : The collaborative network of the Cellular Therapy
Committee of the Children’s Oncology Group. Abbreviations: ALL – Acute
lymphoblastic leukemia, AML – Acute myelogenous leukemia, NB –
neuroblastoma, CNS – Central nervous system, CCL – Cancer Control, AYA
– Adolescent and young adult, PTCTC – Pediatric Transplant and
Cellular Therapy Consortium, BMT CTN – Bone marrow transplant clinical
trials network.
Figure 2 : Intricate logistics involved in delivery of novel
cellular therapy, including potential patient barriers. Adapted from
ASTCT-NMDP ACCESS Initiative presentation, provided by Jeffrey Auletta.
Figure 1: